Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia
Authors:
- Margot J. MelliesMMMargot J. Mellies
- Peter S. GartsidePGPeter S. Gartside
- Lenora GlatfelterLGLenora Glatfelter
- Peter VinkPVPeter Vink
- Greg GuyGGGreg Guy
- Gustav SchonfeldGSGustav Schonfeld
- Charles J. GlueckCGCharles J. Glueck
- 1 October 1980
- journal article
- research article
- Published by Elsevier in Metabolism
- Vol. 29 (10) , 956-964
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Drug management of hypercholesterolemiaAmerican Heart Journal, 1979
- Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia.Circulation, 1979
- A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.Heart, 1978
- Colestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortalityJournal of Chronic Diseases, 1978
- A comparison of cholestyramine and nicotinic acid in the treatment of familial type II hyperlipoproteinaemia.1977
- Long-term Changes of Serum Cholesterol with Cholesterol-altering Drugs in Patients with Coronary Heart DiseaseCirculation, 1974
- The Structure of Human High Density Lipoprotein and the Levels of Apolipoprotein A-I in Plasma as Determined by RadioimmunoassayJournal of Clinical Investigation, 1974
- Probucol in the long-term treatment of hypercholesterolaemiaCurrent Medical Research and Opinion, 1973
- Mode of action of a new hypocholesteraemic drug (DH-581) in familial hypercholesteraemiaAtherosclerosis, 1972
- The effect of [4,4′-(isopropylidenedithio)bis(2,6-di-t-butylphenol)] (DH-581) on serum lipids and lipoproteins in human subjectsMetabolism, 1969